IceCure Medical Ltd. (NASDAQ: ICCM) Quarterly Earnings Preview

Core Insights - IceCure Medical Ltd. specializes in cryoablation technology, a minimally-invasive method for tumor destruction through freezing, and is set to release quarterly earnings on November 19, 2025, with Wall Street expecting an EPS of -$0.05 and revenue of approximately $714,000 [1] Financial Performance - The company has a negative price-to-earnings (P/E) ratio of -2.67, indicating negative earnings, and a negative earnings yield of -37.46%, highlighting ongoing financial difficulties [2] - ICCM's price-to-sales ratio stands at 17.53, suggesting that investors are willing to pay $17.53 for every dollar of sales [2] - The enterprise value to sales ratio is 16.45, slightly lower than the price-to-sales ratio, reflecting the company's valuation including its debt [3] - The enterprise value to operating cash flow ratio is -3.23, indicating challenges in generating positive cash flow from operations [3] Debt and Liquidity - ICCM has a debt-to-equity ratio of 0.82, showing a moderate level of debt compared to its equity, indicating that the company is not overly reliant on debt for financing [4] - The current ratio of 1.18 suggests that ICCM has a reasonable level of liquidity to cover its short-term liabilities, providing some financial stability amidst its challenges [4]